PET imaging trial partnerships
Neurology PET trial imaging, under one contract
Amavita Research is a clinical trial site and PET imaging trial partner. Our North Miami Beach site runs cardiovascular trials; for neurology trials where PET imaging drives eligibility and endpoints, we contract as the prime imaging-trial partner — one contract, one project manager, PET delivered through our qualified imaging network.
Neurology trials live or die on molecular imaging. Amyloid PET confirms Alzheimer's pathology for enrollment. Tau PET stages disease and measures treatment effect. Alpha-synuclein PET is opening Parkinson's and MSA programs. Neuroinflammation (TSPO) PET is becoming a pharmacodynamic readout. Each tracer brings its own acquisition protocol, reader qualification, and QC burden.
Amavita Research absorbs that burden by contracting as the prime imaging-trial partner. Sponsors sign one contract with one accountable owner: feasibility, budget, imaging charter adherence, tracer coordination, DICOM transfer and QC, and monitor access all run through a single project manager and a single PI team. PET imaging executes through our qualified imaging network — PET/CT, F-18 tracer capability, GCP and 21 CFR Part 11 controls.
This is the same operating discipline behind our cardiovascular site: 7 active trials, GCSA-certified through February 2027, and a last program that went from CTA to first-patient-in in 41 days. We bring that startup speed and audit-ready process to PET-centric neurology programs.
PET tracers and modalities we coordinate
- Amyloid PET — Alzheimer's enrollment confirmation and pathology staging
- Tau PET (F-18 class) — disease staging and treatment-effect measurement
- Alpha-synuclein PET — Parkinson's disease and MSA programs
- Neuroinflammation (TSPO) PET — microglial activation and pharmacodynamic readouts
- F-18 tracer coordination through the qualified imaging network
What makes neurology PET operationally hard
- Tracer-specific acquisition protocols and reader qualification per study
- Eligibility-gated imaging with central-read turnaround pressure
- Longitudinal imaging endpoints requiring tight visit-window control
- Imaging charter adherence, DICOM QC, and de-identification at scale
What sponsors get
- One contract, one project manager, one PI team
- Feasibility in days, with a 20-minute sponsor consultation led by our COO
- GCP-compliant imaging operations with 21 CFR Part 11 controls
- Audit-ready documentation from a GCSA-certified organization
How the prime model works
| Dimension | Amavita Research |
|---|---|
| Contracting | Amavita is the prime contractor to the sponsor. Imaging executes as a qualified subcontracted workstream — no direct sponsor-to-imaging-vendor contracting. |
| Accountability | One project manager owns feasibility, budget, imaging reads, and monitor access. Enrollment through imaging reads runs under one team. |
| Imaging delivery | PET imaging delivered through our qualified imaging network — PET/CT acquisition, F-18 tracer coordination, per-charter reads, DICOM transfer and QC. |
| Patient enrollment | Cardiovascular enrollment happens at our North Miami Beach site. For neurology PET trials, Amavita serves as the prime imaging-trial partner, not the enrolling site. |
| Quality | GCSA-certified through February 2027. GCP and 21 CFR Part 11 controls on imaging data. Zero FDA Form 483 findings to date. |
Frequently asked questions
Does Amavita enroll neurology patients at its North Miami Beach site?
No. Our North Miami Beach site enrolls cardiovascular trials. For neurology trials, Amavita contracts as the prime imaging-trial partner: we own the sponsor contract, project management, and imaging coordination, with PET imaging delivered through our qualified imaging network.
What does 'prime imaging-trial partner' mean for our CTA?
The sponsor signs one clinical trial agreement with Amavita Research Services. Amavita owns contracting, invoicing, project management, and the imaging workstream. Imaging sites operate as qualified subcontractors under Amavita's oversight — the sponsor never has to contract or manage them directly.
Which neurology PET tracers can you support?
Amyloid PET, tau PET (F-18 class), alpha-synuclein PET, and neuroinflammation (TSPO) PET, plus F-18 tracer coordination — all executed per the study imaging charter through our qualified imaging network.
How do you handle central reads and imaging charters?
Imaging executes per the study imaging charter: standardized acquisition, DICOM transfer and QC, de-identification, and reader workflow coordination — under GCP and 21 CFR Part 11 controls, managed by one Amavita project manager.
Who owns the sponsor relationship?
Amavita does. Sponsor consultations, feasibility, and operational follow-through are owned by Nereisy Alonso, COO. One contact, same-business-day response.
Next step
Schedule a 20-minute feasibility call
Talk with Nereisy Alonso, COO — she owns all sponsor consultations. Feasibility, budget, contracts, and monitor access from a single owner, with same-business-day response.